Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
10.69
+0.61 (6.05%)
At close: Mar 31, 2026, 4:00 PM EDT
10.51
-0.18 (-1.68%)
After-hours: Mar 31, 2026, 7:36 PM EDT

Elicio Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----28.31
Revenue Growth (YoY)
----883.06%
Cost of Revenue
----0.43
Gross Profit
----27.88
Selling, General & Admin
12.8111.3311.95.6318.49
Research & Development
24.933.6623.8518.148.7
Total Operating Expenses
37.7144.9935.7523.7367.19
Operating Income
-37.71-44.99-35.75-23.73-39.31
Interest Income
0.780.780.370.07-0.1
Interest Expense
1.130.461.063.6-
Other Non-Operating Income (Expense)
-1.5-0.231.24-0.940.26
Total Non-Operating Income (Expense)
0.4112.672.720.16
Pretax Income
-37.31-43.98-33.08-21.01-39.15
Net Income
-39.57-51.9-35.2-28.21-54.57
Net Income to Common
-39.57-51.9-35.2-28.21-54.57
Shares Outstanding (Basic)
1512511
Shares Outstanding (Diluted)
1512511
Shares Change (YoY)
25.48%141.35%242.51%--
EPS (Basic)
-2.58-4.25-6.96-89.27-19.30
EPS (Diluted)
-2.58-4.25-6.96-89.27-19.30
Shares Outstanding
17.811.039.63.013
Free Cash Flow
-36.97-37.16-32.76-22.83-53.03
Free Cash Flow Per Share
-2.41-3.04-6.48-15.47-35.92
Gross Margin
----98.47%
Operating Margin
-----138.84%
Profit Margin
-----192.76%
FCF Margin
-----187.29%
EBITDA
-36.59-43.81-34.58-22.68-38.51
EBITDA Margin
-----136.01%
EBIT
-37.71-44.99-35.75-23.73-39.31
EBIT Margin
-----138.84%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q